Media Outlet:
Hardman & Co
Author:
Martin Hall
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from early-stage development via venture capital (SV Health Investors funds) through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and with an experienced investment management team. Over the last five years, IBT’s NAV has increased 62%, while the share price has increased 92% over the same period – the superior returns generally reflected by a share price premium.
Published on 6th July 2021
Hardman & Co
Martin Hall